Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: MGTX

MeiraGTx Holdings plc

Healthcare | Biotechnology

No licensed closing price on file for MGTX. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$0.71

MeiraGTx Holdings plc (NASDAQ: MGTX) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 09:35 UTC.

What MeiraGTx Holdings plc does

MeiraGTx is a clinical-stage genetic medicines company developing treatments for inherited and common diseases with severe unmet needs, including radiation-induced xerostomia, Parkinson's disease, and retinal dystrophy. The company operates vertically integrated manufacturing facilities in London and Shannon that produce viral vectors, plasmid DNA, and conduct quality control testing to support its clinical pipeline and commercial supply.

Summarized from MeiraGTx Holdings plc’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
EPS (TTM)$0.71
Return on equity1,971.36%

Revenue, margins & earnings

FY2021: net loss $80M on revenue $38M$38MFY2021FY2022: net loss $130M on revenue $16M$16MFY2022FY2023: net loss $84M on revenue $14M$14MFY2023FY2024: net loss $148M on revenue $33M$33MFY2024FY2025: net loss $114M on revenue $81M$81MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-06
  • 2026-10-06CHIEF SCI OFCR, OPHTHALMOLOGYSale-27,659$294.3K
  • 2026-09-24DirectorRestricted Share UnitsAward100,000—
  • 2026-08-18PRESIDENT & CEOSale-62,000$859.3K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does MeiraGTx Holdings plc do?

MeiraGTx is a clinical-stage genetic medicines company developing treatments for inherited and common diseases with severe unmet needs, including radiation-induced xerostomia, Parkinson's disease, and retinal dystrophy.

When did MGTX last file with the SEC?

MeiraGTx Holdings plc's most recent SEC filing on record is a 8-K filed 2026-07-07. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 09:35 UTC. This page is also available as JSON at /api/data?ticker=MGTX and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for MGTX and 5,000+ tickers.

Create a free account — keep MGTX
For your agent
GET /api/data?ticker=MGTX

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt